IMAGIN MEDICAL INC - IMEXF STOCK NEWS

On April 22, 2022, Imagin Medical (CSE: IME, OTCQB: IMEXF) announced the granting of 472,187 stock options to employees, board members, and consultants, within its Stock Option Plan. These options have an exercise price of $0.28 USD per share and are valid for five years, expiring on April 22, 2027. Imagin Medical specializes in surgical imaging, focusing on innovative technologies for visualizing cancer during minimally invasive procedures, with its flagship product being the i/Blue™ Imaging System aimed at improving bladder cancer treatment.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) has announced significant changes to its Board of Directors. Dr. Robin Atlas has resigned, and Kayvon Namvar joins as Chair of the Audit Committee. Kevin Slawin, M.D., the lead investor, becomes Board Chairman. The Company achieved a major milestone by moving its i/Blue Imaging System to pre-production, setting the stage for FDA submission in late 2022. CEO Jim Hutchens expressed optimism about meeting development milestones and the potential impact of their technology on cancer care.

Imagin Medical has secured a new convertible note financing of US$3 million from Rapha Capital BioVentures Fund I, LP, to advance the clinical development of its i/Blue™ Imaging System. Notably, Kevin Slawin, M.D., will join the board as part of this financing. The offering includes a 10% annual interest rate and will convert to shares at US$0.40 upon completion of an additional equity financing of at least US$2 million. The notes will mature in 24 months and are fully secured by the company's assets.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) announced that the final design of its i/Blue Imaging System™ will be showcased at the American Urology Association Annual Meeting in September. This annual event, the largest for urologists globally, presents an opportunity for Imagin to demonstrate the system's capabilities in visualizing bladder cancer. The design incorporates FDA feedback and has met critical verification requirements through benchmark testing, enhancing its sensitivity and clinical application potential.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) reports progress towards commercial-stage manufacturing through Lighthouse Imaging. The i/Blue Imaging System™ will be demonstrated at the American Urology Association meeting in September, highlighting enhancements against competitors. Updates based on FDA feedback aim to improve system performance, backed by successful testing of contrast-induced fluorescence. The initiative may lead to unique intellectual property and a stronger market demand for blue light cystoscopy, which patients increasingly prefer for bladder cancer detection.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) has made significant progress toward commercial-stage manufacturing of its i/Blue Imaging System™ with Lighthouse Imaging. After receiving functional feasibility units from Optel, Lighthouse is refining the design to meet FDA standards. The company remains optimistic despite COVID-19 delays, as Lighthouse's program is on schedule. Imagin aims to enhance cancer visualization, specifically for bladder cancer, to improve detection and reduce recurrence rates.

Imagin Medical (CSE: IME) (OTCQB: IMEXF) announced the closing of the second tranche of its Convertible Note offering, raising US$1,415,500. This brings the total amount raised to US$2,165,500. All securities related to this offering are subject to a statutory hold period of four months plus a day. Imagin is focused on enhancing cancer visualization during minimally invasive surgeries, particularly for bladder cancer, through its i/Blue™ Imaging System.

Imagin Medical Inc. has successfully closed the first tranche of a proposed offering of Convertible Notes, raising US$750,000 as part of a potential total of US$3 million. The securities issued will be subject to a statutory hold period of four months plus a day. Imagin Medical focuses on innovative surgical imaging technology, primarily targeting bladder cancer detection and treatment. The company's first product, the i/Blue Imaging System, aims to enhance cancer removal accuracy and reduce recurrence rates.

Imagin Medical Inc. (CSE:IME)(OTCQB:IMEXF) has announced plans to offer up to US$3 million in Convertible Notes and perform a 20-for-1 share consolidation. The Notes will bear a 10% interest rate, maturing in 18 months with a conversion price of US$0.02 per unit before consolidation. The first tranche of US$750,000 is expected to close on October 22, 2020, pending regulatory approval. The consolidation aims to reduce the number of outstanding shares and increase conversion prices.